The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...
Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer's disease, ALS and other brain ...
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...
Lilly will add the center to a site in Lebanon, Indiana, where it is already spending about $9 billion to improve ...
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...
Health care stocks underperformed the broader market in 2023, with many companies falling short of their profit targets, and ...
7don MSN
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
As Eli Lilly has surged to become the most valuable company in biopharma—with a market cap now more than twice that of ...
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are ...
Indianapolis-based Eli Lilly’s supply of Mounjaro, which is used to treat Type 2 diabetes, and popular weight-loss drug ...
U.S. drugmaker Eli Lilly said on Wednesday it will invest $4.5 billion to create a new center for advanced manufacturing and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback